During the treatment of chronic inflammatory diseases such as RA, our current therapeutic armory that is increasingly build on monoclonal antibodies, is already able to successfully target both fibroblast-derived cytokines such as IL-6 as well as macrophage-derived cytokines such as TNF and thus interfere with the inflammatory crosstalk between both cell types (4). This evidence concerns the gene IL6 and rheumatoid arthritis.